ライフサイエンスコーパス: transfusion

1 ral line, intracranial hemorrhage, and blood transfusion).

2 lerated tumor growth which was halted by PMP transfusion.

3 RBCs) and subsequent lung inflammation after transfusion.

4 in lower platelet count increments following transfusion.

5 revious transplantation, pregnancy, or blood transfusion.

6 e development of lung injury following blood transfusion.

7 iming as well as the location of the initial transfusion.

8 t count increment 10 to 90 minutes following transfusion.

9 an section requires donor (allogeneic) blood transfusion.

10 requiring treatment and postprocedural blood transfusion.

11 s measured before and at defined times after transfusion.

12 own to contribute to lung inflammation after transfusion.

13 higher (7 d) primaquine dose required blood transfusion.

14 r parameters and microvascular changes after transfusion.

15 25 x 10(9) platelets per L or greater after transfusion.

16 the potential to replace donor platelets for transfusion.

17 -day survival than delayed transfusion or no transfusion.

18 age duration for red cells to 5 weeks before transfusion.

19 re may exacerbate vascular injury during RBC transfusion.

20 een hemorrhagic shock patients requiring RBC transfusion.

21 clinical requirement to prevent any risks in transfusion.

22 were the most common indications for massive transfusion.

23 row failure, requiring prophylactic platelet transfusion.

24 platelet function for prophylactic platelet transfusion.

25 linical improvement and outweigh the risk of transfusion.

26 t, lung, and stem-cell transplant, and blood transfusion.

27 r and an intended recipient prior to a blood transfusion.

28 Patients were followed from first blood transfusion.

29 is confounded by potential concomitant blood transfusion.

30 rk Field imaging device before and after RBC transfusion.

31 erum ERFE levels, which decrease after blood transfusion.

32 Israel, and the USA and expected to need RBC transfusions.

33 s of less than 10 x 10(9) per L; or platelet transfusions.

34 resonance imaging before and after exchange transfusions.

35 n plasma (6 [2, 10] vs 6 [2, 12], P = 0.032) transfusions.

36 incurable diseases, immunotherapy and blood transfusions.

37 that aim to reduce or eliminate unnecessary transfusions.

38 d blood loss, fluid resuscitation, and blood transfusions.

39 undergoing major surgery often receive PRBC transfusions.

40 n may be an alternative to fully HLA-matched transfusions.

41 ology/oncology patients in spite of platelet transfusions.

42 ects of restrictive transfusion protocols on transfusions.

43 tervention Triage) and requirement for blood transfusions.

44 requently become dependent on red blood cell transfusions.

45 tation (2.9% versus 8.0%; P<0.001) and blood transfusion (12.8% versus 22.9%; P<0.001).

46 ury (20.8% vs 13.8%, P < .001), 30-day blood transfusion (3.4% vs 2.7%, P < .01), and 1-year readmiss

47 bleeding (14.0% versus 0.9%; P<0.001), blood transfusion (3.7% versus 0.2%; P<0.001), and death (10.0

48 1.00; 95% CI: 0.50 to 1.99; p = 0.99), blood transfusions (4.8% vs. 4.5%; HR: 1.09; 95% CI: 0.51 to 2

49 than 8 (31.5% vs 10.7%; P < .001), 4 or more transfusions (51.4% vs 17.6%; P < .001), operation time

50 injury (54.8% vs 25.3%; P < .001), 4 or more transfusions (74.2% vs 39.6%; P < .001), operation time

51 enced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity.

52 aT is a lifelong dependence on regular blood transfusions, a consequence of which is systemic iron ov

53 sk, 1.34; 95% CI, 1.10 to 1.62; P=0.001) and transfusion (absolute risk, 1.8% vs. 1.5%; relative risk

54 nt with asplenia and multiple red blood cell transfusions acquired babesiosis infection with Babesia

55 rrin-bound iron (P < 0.001) as compared with transfusion after 1 to 5 weeks of storage.

56 d, autologous, leukoreduced, packed red cell transfusion after 1, 2, 3, 4, 5, or 6 weeks of storage (

57 lation-based cohort of patients who received transfusions, allowing detection of small yet clinically

58 of red-cell storage affects mortality after transfusion among critically ill adults.

59 The frequency of RBC transfusion among patients with severe (hematocrit, < 21

60 Among 24,230 patients, 29% received a transfusion and 4% developed sepsis.

61 tissue cryopreservation for transplantation, transfusion and basic biomedical research, as well as te

62 effect with those who both received a blood transfusion and developed sepsis having even worse survi

63 However, receiving a transfusion and developing sepsis has an additive effect

64 Conventional management primarily relies on transfusion and iron-chelation therapy, as well as splen

65 Secondary outcomes included red-cell transfusion and other clinical outcomes.

66 After risk adjustment, transfusion and sepsis were associated with worse colon

67 otently impact immune outcomes following RBC transfusion and suggest that RBCs with altered Ag levels

68 ching was used to account for confounders of transfusion and thrombotic risk.

69 Initiation of prehospital transfusion and time from MEDEVAC rescue to first transf

70 To examine the association of prehospital transfusion and time to initial transfusion with injury

71 The sensitivity analysis including daily transfusions and fluid balance (in a subset of 518 patie

72 sitivity analysis further adjusted for daily transfusions and fluid balance in a subset of our patien

73 urrently available treatments are limited to transfusions and hydroxycarbamide, although stem cell tr

74 es, 30-day acute kidney injury, 30-day blood transfusion, and 1-year readmission rates for myocardial

75 fety outcomes included major bleeding, blood transfusion, and hospitalization for bleeding.

76 ospital length of stay, hemorrhage requiring transfusion, and permanent pacemaker implantation (P<0.0

77 collected included demographics, infections, transfusions, and outcomes.

78 Bleeding complication was defined as any transfusion, any hemorrhage or hematoma, or the need for

79 n worldwide, although optimal thresholds for transfusion are debated.

80 Perioperative blood transfusions are associated with infectious complication

81 Perioperative blood transfusions are associated with shorter survival, indep

82 Red blood cell (RBC) transfusions are of vital importance in patients with si

83 Blood transfusions are the mainstay of stroke prevention in pe

84 n enabling platform to mechanistically study transfusion-associated pulmonary vascular complications

85 Prophylactic platelet transfusion at defined platelet count thresholds is stil

86 t experienced centers may receive a platelet transfusion at the first sign of bleeding, rather than p

87 125-0.5 mg/kg vs 0.75-1.75 mg/kg); pre-study transfusion burden (high transfusion burden vs low trans

88 etic features, profound cytopenias, and high transfusion burden are candidates for HSCT.

89 cell units over 8 weeks versus pre-treatment transfusion burden in high transfusion burden patients.

90 r from baseline for 14 days or longer in low transfusion burden patients, and a reduction in red bloo

91 sus pre-treatment transfusion burden in high transfusion burden patients.

92 5 mg/kg); pre-study transfusion burden (high transfusion burden vs low transfusion burden, defined as

93 usion burden (high transfusion burden vs low transfusion burden, defined as >/=4 vs <4 red blood cell

94 (and baseline haemoglobin <10 g/dL), or high transfusion burden, defined as requiring 4 or more red b

95 olled patients were classified as having low transfusion burden, defined as requiring less than 4 red

96 ransfusion protocols to reduce avoidable RBC transfusions, but evidence of their effectiveness in pra

97 graft and new red cell antibodies induced by transfusion can lead to immunohaematological complicatio

98 Although RBC transfusion can result in the development of anti-RBC al

99 Sequential expansion of blood transfusion capability after 2012 to deployed military m

100 ible alternative for fractionating blood for transfusion, cellular therapy and blood-based diagnostic

101 The change in microvascular perfusion after transfusion correlated negatively with baseline microvas

102 of-of-principle study, we determined whether transfusion could augment cerebral oxygen delivery, part

103 intravenous fluids, vasopressors, and blood transfusion decreases mortality among Zambian adults wit

104 stem and the randomisation was stratified by transfusion dependence and by baseline total symptom sco

105 Transfusion dependency was the only clinical variable as

106 RBC transfusion did not affect overall mortality in critical

107 o define which patients can benefit from RBC transfusion during cardiovascular resuscitation.

108 aboratory sampling is a major contributor to transfusion during ECMO.

109 tegy (hemoglobin threshold, < 7 g/dL) of RBC transfusion during ICU stay.

110 a, who account for nearly 90% of all massive transfusion events.

111 2% female) who received 59320 red blood cell transfusions exclusively from 1 of 3 types of donors (88

112 ixture cohort (ie, either all red blood cell transfusions exclusively from male donors, or all exclus

113 an arterial pressure (>/=65 mm Hg) and blood transfusion (for patients with a hemoglobin level <7 g/d

114 For receipt of transfusion from a never-pregnant female donor vs male d

115 ed red blood cell transfusions, receipt of a transfusion from an ever-pregnant female donor, compared

116 ntify the association between red blood cell transfusion from female donors with and without a histor

117 854 862 adult patients who received transfusions from 2003 to 2012.

118 cipient dogs received up to 8 weekly treated transfusions from a single donor (a highly immunogenic s

119 Red blood cell transfusions from ever-pregnant or never-pregnant female

120 ssociation between mortality and exposure to transfusions from ever-pregnant or never-pregnant female

121 female donors, compared with red blood cell transfusions from male donors.

122 Transfusions from never-pregnant female donors were not

123 ictive transfusion group than in the liberal transfusion group (mean difference -1.73 units, 95% CI -

124 nits transfused was lower in the restrictive transfusion group than in the liberal transfusion group

125 ates and replaces the previous ASCO platelet transfusion guideline published initially in 2001.

126 e colon cancer disease-specific survival [(+)transfusion: hazard ratio (HR) 1.19, 95% confidence inte

127 After transfusion, hemoglobin rose from 9.6 +/- 1.4 to 10.8 +/

128 cardiovascular disease-specific survival [(+)transfusion: HR 1.18, 95% CI 1.04-1.33; (+)sepsis: HR 1.

129 95% CI 1.58-2.63], and overall survival [(+)transfusion: HR 1.21, 95% CI 1.14-1.29; (+)sepsis: HR 1.

130 perioperative factors, including anesthesia, transfusions, hypothermia, and postoperative complicatio

131 This study demonstrates that RBC transfusion improves cerebral oxygen delivery globally a

132 RBC transfusion improves sublingual microcirculation indepen

133 mplications occurred in 7.0% of cases, blood transfusion in 17.5%, clinical stroke in 1.8%, and pacem

134 6%, and was the sole reason for at least one transfusion in 42.2% of patients.

135 childhood, requiring >/=1 blood or platelet transfusion in 78% of cases.

136 protocols independently reduced the odds of transfusion in moderate anemia with an odds ratio of 0.5

137 Other recommendations address platelet transfusion in patients with hematologic malignancies or

138 idence-based guidance on the use of platelet transfusion in people with cancer.

139 ines (the use of leukoreduction and platelet transfusion in solid tumors or chronic, stable severe th

140 a previous recommendation involved platelet transfusion in the setting of hematopoietic stem-cell tr

141 ese data suggest that greater than 1:2 ratio transfusion in the setting of massive hemorrhage may not

142 The findings support prehospital transfusion in this setting.

143 Prehospital blood product transfusion in trauma care remains controversial due to

144 Transfusions increased hemoglobin (Hb; from 9.1 to 10.3

145 nt with immunosuppressive agents, leading to transfusion independence or complete recovery of periphe

146 t of patients treated with decitabine became transfusion independent compared with 16% of patients tr

147 PMP transfusion inhibited growth of both lung and colon carc

148 NL-parasitized red blood cells (pRBCs) after transfusion into naive or acutely infected mice.

149 RBC transfusion is often required in patients with sepsis.

150 Platelet transfusion is often used to restore hemostasis during o

151 donors on patient outcome following platelet transfusion is unknown.

152 ood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as weekly maternal IV immun

153 and in estimated blood loss, intraoperative transfusion, length of stay, and postoperative complicat

154 This approach to platelet transfusion may be particularly important when supportin

155 eic SCT or chemotherapy and because platelet transfusions may not prevent bleeding, other risk factor

156 and thrombosis, and different thresholds for transfusion, may be appropriate subjects of future trial

157 The restrictive group received fewer blood transfusions: mean 20.3 +/- 32.7 units, median = 8 (inte

158 bility could be explored for applications in transfusion medicine but also for delivery of nucleic ac

159 AABB and the International Collaboration for Transfusion Medicine Guidelines (the use of leukoreducti

160 AABB and the International Collaboration for Transfusion Medicine Guidelines.

161 In a dog platelet transfusion model, we have evaluated other methods of pr

162 Among female recipients of red blood cell transfusions, mortality rates for an ever-pregnant femal

163 atients with perforation including bleeding, transfusion, myocardial infarction, and death.

164 Red-cell transfusion occurred in 52.3% of the patients in the res

165 ciated with 23% lower odds of receiving PRBC transfusion (odds ratio = 0.77, 95% confidence interval

166 ivariable analysis, only receiving 4 or more transfusions (odds ratio [OR], 3.47; 95% CI, 2.04-5.91),

167 Transfusion of "older" blood products may contribute to

168 g for confounders on multivariable analysis, transfusion of "older" blood remained independently asso

169 d an adjusted odds ratio for receiving blood transfusion of 1.93 (95% CI, 1.21-3.07) compared with wo

170 patients, and a reduction in red blood cell transfusion of 4 or more red blood cell units or a 50% o

171 Transfusion of aged pRBCs or microparticles isolated fro

172 Massive transfusion was defined as the transfusion of at least 10 U of RBCs in the first 24 hou

173 After 6 weeks of refrigerated storage, transfusion of autologous red cells to healthy human vol

174 Transfusion of blood products should not be withheld fro

175 Transfusion of either platelets or red blood cells (RBCs

176 We hypothesized that transfusion of leukocytes loaded ex vivo with the lipoph

177 After transfusion of one unit of RBC, hemoglobin concentration

178 Transfusion of one unit of RBCs.

179 Transfusion of platelets poses significant challenges of

180 This was attenuated after transfusion of pRBCs treated with amitriptyline or from

181 Transfusion of RBC significantly decreased the flow hete

182 Transfusion of RBC significantly increased microcirculat

183 Transfusion of red blood cells expressing self-antigen e

184 Transfusion of red blood cells from female donors has be

185 times the lethal dose (LD50) of BoNT/A, and transfusion of these red blood cells into naive mice aff

186 ressible hemorrhage still heavily depends on transfusion of whole blood or blood's hemostatic compone

187 Transfusion of wild-type platelets into platelet-specifi

188 g inflammation was studied in mice receiving transfusions of pRBCs and microparticles isolated from t

189 tient-level analyses were conducted with RBC transfusion on day of enrollment as the outcome and admi

190 of traumatic brain injury (TBI) and massive transfusion on fibrinolysis status.

191 those seeking to assess effects of anemia or transfusion on lung function).

192 The effects of RBC transfusion on microvascular perfusion are not well docu

193 We investigated the effect of RBC transfusion on sublingual microcirculation in hemorrhagi

194 The effect of platelet transfusions on IGF-1R was explored.

195 ect of PRBC age (ie, storage duration before transfusion) on perioperative surgical outcomes remains

196 treatments (MISC), whereas 697 received RBC transfusions only.

197 incidence of bleeding (blood loss requiring transfusion or intracranial hemorrhage) and thrombosis d

198 ter 24-hour and 30-day survival than delayed transfusion or no transfusion.

199 95% CI 1.09-1.91), and intraoperative blood transfusion (OR 1.45, 95% CI 1.15-1.83) were weak predic

200 ore widespread implementation of restrictive transfusion policies for adults with acute upper gastroi

201 Red blood cell (RBC) transfusion poses significant risks to critically ill pa

202 scitation has become integrated into massive transfusion practice, there is a paucity of evidence sup

203 the impact of implementing a PBM program on transfusion practices and perioperative clinical outcome

204 Restrictive perioperative transfusion practices are a possible strategy to reduce

205 oglobin values and suggests that restrictive transfusion practices may not be appropriate in this pop

206 at causalities in Afghanistan, blood product transfusion prehospital or within minutes of injury was

207 ed a priori, to compare rates of donor blood transfusion (primary outcome) and fetomaternal haemorrha

208 During RBC transfusion, production of alloantibodies against RBC no

209 Extravascular hemolysis after transfusion progressively increased with increasing stor

210 e and admission to an ICU with a restrictive transfusion protocol as the exposure of interest.

211 ld (hematocrit, > 30%) anemia in restrictive transfusion protocol ICUs was 67%, 19%, and 4%, respecti

212 s (41.6%) were in an ICU with an restrictive transfusion protocol.

213 2% for those in ICUs without an restrictive transfusion protocol.

214 Of the 59 study ICUs, 24 had an restrictive transfusion protocol; 2,510 patients (41.6%) were in an

215 munization and may benefit from personalized transfusion protocols and/or targeted therapies.

216 justing for confounding factors, restrictive transfusion protocols independently reduced the odds of

217 essed the independent effects of restrictive transfusion protocols on transfusions.

218 ports the efficacy and safety of restrictive transfusion protocols to reduce avoidable RBC transfusio

219 udy is a retrospective review of all massive transfusions provided in an urban academic hospital from

220 adverse events have been associated with RBC transfusion, raising safety concerns.

221 Donor blood transfusion rate was 3.5% in the control group versus 2.

222 In a planned subgroup analysis, the transfusion rate was 4.6% in women assigned to control v

223 The practice of a high transfusion ratio of fresh frozen plasma (FFP) to red bl

224 High FFP:RBC transfusion ratios are applied mostly to patients withou

225 Examination of FFP:RBC transfusion ratios for patients without trauma.

226 against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatib

227 he probability of life-threatening hemolytic transfusion reactions, not all patients generate anti-RB

228 can cause life-threatening delayed hemolytic transfusion reactions.

229 ating a risk for Vel blood typing errors and transfusion reactions.

230 Among patients who received red blood cell transfusions, receipt of a transfusion from an ever-preg

231 Retrospective cohort study of first-time transfusion recipients at 6 major Dutch hospitals enroll

232 All transfusion recipients in Sweden and Denmark.

233 62 recipients vs 68 deaths among 324 delayed transfusion recipients or nonrecipients).

234 Transfusion recipients were compared with nonrecipients

235 At all thresholds, transfusions reduced the volume of peak OEF found in the

236 assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when compared with

237 fusion and time from MEDEVAC rescue to first transfusion, regardless of location (ie, prior to or dur

238 Time to initial transfusion, regardless of location (prehospital or duri

239 ury (acute respiratory distress syndrome and transfusion-related acute lung injury), for assessment o

240 the highest rate of acceptance for platelet transfusions reported in either animals or man.

241 Laboratory sampling contributed to transfusion requirement in 56.6%, and was the sole reaso

242 examic acid (TXA) in reducing blood loss and transfusion requirements during liver transplantation.

243 appears effective in reducing red blood cell transfusion requirements without increasing the risk of

244 re, surgery length, operative blood loss, or transfusion requirements, but was positively associated

245 cute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR had higher rates

246 ith major burns have major (>1 blood volume) transfusion requirements.

247 latelet counts, and ten had reduced platelet transfusion requirements.

248 (33.3%) and 9 of 282 (3.4%) receiving 2 or 3 transfusions, respectively.

249 In vulnerable brain regions, transfusion resulted in a greater (16%) rise in oxygen d

250 study has investigated the association among transfusion, sepsis, and disease-specific survival in po

251 33; (+)sepsis: HR 1.63, 95% CI 1.14-2.31; (+)transfusion/(+)sepsis: HR 2.04, 95% CI 1.58-2.63], and o

252 30; (+)sepsis: HR 1.84, 95% CI 1.44-2.35; (+)transfusion/(+)sepsis: HR 2.27, 95% CI 1.87-2.76], cardi

253 29; (+)sepsis: HR 1.76, 95% CI 1.48-2.09; (+)transfusion/(+)sepsis: HR 2.36, 95% CI 2.07-2.68] relati

254 s: HR 2.36, 95% CI 2.07-2.68] relative to (-)transfusion/(-)sepsis.

255 the liberal (n = 149) or to the restrictive transfusion strategy (n = 151) group.

256 A restrictive transfusion strategy halved blood product utilization.

257 comes of a restrictive to a liberal red cell transfusion strategy in 20% or more total body surface a

258 The optimal transfusion strategy in major burn injury is thus needed

259 observed a survival trend favoring a liberal transfusion strategy in patients with septic shock when

260 ect of a restrictive versus liberal red-cell transfusion strategy on clinical outcomes in patients un

261 7-8 g/dL) or liberal (hemoglobin 10-11 g/dL) transfusion strategy throughout hospitalization.

262 d had anaemia with or without red blood cell transfusion support.

263 omes were complications, death, and need for transfusions, surgery, or angiography.

264 in the screening period of 4 weeks: platelet transfusion, symptomatic bleeding, or platelet count of

265 ere hypoxemia are expected outcomes from RBC transfusion that need to be weighted with its benefits i

266 ed specific tolerance to 8 more weekly donor transfusions that had not been treated.

267 complications of iron overload, arising from transfusions that represent the basis of disease managem

268 defined as the absence of rebleeding, blood transfusion, therapeutic intervention, 28 day readmissio

269 enty-one children with SCA receiving chronic transfusion therapy (CTT) underwent magnetic resonance i

270 s whereby both increased iron absorption and transfusion therapy contribute to the iron overload.

271 However, a major complication of transfusion therapy is alloimmunization.

272 r cardiac surgery) to a restrictive red-cell transfusion threshold (transfuse if hemoglobin level was

273 duction of anesthesia) or a liberal red-cell transfusion threshold (transfuse if hemoglobin level was

274 Zika virus in semen, the potential for blood-transfusion transmission, mother-to-child transmission,

275 This is believed to be the first transfusion-transmitted case and the fifth documented ca

276 currently the number one cause of reportable transfusion-transmitted infection in the United States.

277 ssociated with fewer patients receiving PRBC transfusion using a liberal trigger hemoglobin concentra

278 perative central venous pressure and greater transfusion volumes.

279 io for mortality associated with prehospital transfusion was 0.26 (95% CI, 0.08 to 0.84, P = .02) ove

280 Blood transfusion was administered to 195 women (2.5%).

281 However, RBC transfusion was associated with increased occurrence of

282 Restrictive transfusion was associated with lower risk of all-cause

283 Massive transfusion was defined as the transfusion of at least 1

284 ared with nonrecipients (unexposed) for whom transfusion was delayed or not given.

285 After 6 weeks of refrigerated storage, transfusion was followed by increases in AUC for serum i

286 h, a restrictive strategy regarding red-cell transfusion was noninferior to a liberal strategy with r

287 verall, in our cohort of 6,016 patients, RBC transfusion was not associated with death (hazard ratio,

288 njury severity, nonrecipients of prehospital transfusion were frequency matched to recipients by mech

289 Only 27% of transfusions were associated with a hematocrit less than

290 Most of these transfusions were received by patients without trauma (7

291 e and postoperative complications, and blood transfusion when undergoing a hysterectomy later in life

292 t 28 days who either required red blood cell transfusions while on ruxolitinib or ruxolitinib dose re

293 should be considered for patients requiring transfusion with a very high risk of alloimmunization an

294 prehospital transfusion and time to initial transfusion with injury survival.

295 In these patients, transfusions with platelets showing low HLA class I expr

296 or grade 4 thrombocytopenia before platelet transfusion, with 25 x 10(9) platelets per L or greater

297 Overall, 282 of 318 (88.7%) received transfusions, with 94 of 282 (33.3%) and 9 of 282 (3.4%)

298 All patients who received massive transfusions within the study period and survived more t

299 leading indication for red blood cell (RBC) transfusion worldwide, although optimal thresholds for t

300 We hypothesized that exchange transfusions would decrease CBF and OEF by increasing Ca

301 and management of refractoriness to platelet transfusion ( www.asco.org/supportive-care-guidelines an